Evidence map›Paper›PMID 24447929›Full record

ArticleInternational journal of molecular sciences2014

Phenoxybenzamine is neuroprotective in a rat model of severe traumatic brain injury.

Thomas F Rau, Aakriti Kothiwal, Annela Rova, Joseph F Rhoderick, David J Poulsen

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. IonStar enables high-precision, low-missing-data proteomics quantification in large biological cohorts.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Thomas F RauDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA. Thomas.Rau@mso.umt.edu.
Aakriti KothiwalDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA. aakriti_kothiwal@yahoo.com.
Annela RovaDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA. annela.rova@umconnect.umt.edu.
Joseph F RhoderickDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA. fred.rhoderick@mso.umt.edu.
David J PoulsenDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA. david.poulsen@umontana.edu.
University of Montana · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenoxybenzamine (PBZ) is an FDA approved α-1 adrenergic receptor antagonist that is currently used to treat symptoms of pheochromocytoma. However, it has not been studied as a neuroprotective agent for traumatic brain injury (TBI). While screening neuroprotective candidates, we found that phenoxybenzamine reduced neuronal death in rat hippocampal slice cultures following exposure to oxygen glucose deprivation (OGD). Using this system, we found that phenoxybenzamine reduced neuronal death over a broad dose range (0.1 µM-1 mM) and provided efficacy when delivered up to 16 h post-OGD. We further tested phenoxybenzamine in the rat lateral fluid percussion model of TBI. When administered 8 h after TBI, phenoxybenzamine improved neurological severity scoring and foot fault assessments. At 25 days post injury, phenoxybenzamine treated TBI animals also showed a significant improvement in both learning and memory compared to saline treated controls. We further examined gene expression changes within the cortex following TBI. At 32 h post-TBI phenoxybenzamine treated animals had significantly lower expression of pro-inflammatory signaling proteins CCL2, IL1β, and MyD88, suggesting that phenoxybenzamine may exert a neuroprotective effect by reducing neuroinflammation after TBI. These data suggest that phenonxybenzamine may have application in the treatment of TBI.

Indexed as

AnimalsBrainBrain InjuriesCell DeathCells, CulturedCell SurvivalChemokine CCL2Drug Evaluation, PreclinicalInterleukin-1betaMaze LearningMemoryMyeloid Differentiation Factor 88NeuronsNeuroprotective AgentsPhenoxybenzamineRatsCcl2 protein, ratChemokine CCL2Interleukin-1betaMyd88 protein, ratMyeloid Differentiation Factor 88Neuroprotective AgentsPhenoxybenzamine

Identifiers

PMID24447929
PMCPMC3907876
OpenAlexW1998783557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.